Akero Therapeutics (AKRO) stock soared 5.76% in the intraday trading session on Thursday, following an analyst upgrade and a bullish price target revision.
BofA Securities upgraded Akero Therapeutics to a "Buy" rating from "Neutral" and raised its price target to $63, implying significant upside potential from the current levels. The bullish stance from the analysts fueled optimism among investors, driving the stock higher.
According to analysts polled by FactSet, Akero Therapeutics currently has an average rating of "Buy" and a mean price target of $72.18, suggesting further upside potential for the stock based on analysts' expectations.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.